iShares Self-Driving EV and Tech vs IDEXX Laboratories, Inc. — how do they compare? iShares Self-Driving EV and Tech trades at $33.17 (market cap $264.50M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 152.9× iShares Self-Driving EV and Tech's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 48,021). Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| IDRV | IDXX | |
|---|---|---|
Market Cap | $264.50M | $40.43B |
Volume | 48,021 | 692,164 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $766.68 |
52-Week Low | $32.68 | $504.70 |
Typical Hold Time | 73 Days | 46 Days |
Enterprise Value | — | $41.32B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Trailing returns across standard periods
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →